Management of puberty in constitutional delay of growth and puberty

F. De Luca, J. Argente, L. Cavallo, E. Crowne, H. A. Delemarre-Van de Waal, C. De Sanctis, S. Di Maio, E. Norjavaara, W. Oostdijk, F. Severi, G. Tonini, G. Trifirò, P. G. Voorhoeve, F. Wu

Research output: Contribution to journalArticlepeer-review


Constitutional delay of growth and puberty (CDGP) is the most common presenting form of short stature, but no single test can infallibly discriminate CDGP and isolated hypogonadotrophic hypogonadism. Management of puberty in CDGP aims to optimise not only growth - maintaining body proportions and improving peak bone mass without impairing growth potential - but also well-being; for example, the distress boys often suffer because of their lack of growth and pubertal progression can affect their school performance and social relationships. Typical sex steroid treatments to induce puberty in boys with CDGP include testosterone (T) enanthate, T undecanoate, mixed T esters, T transdermal patches, and oxandrolone p.o. Compared with other regimens, short-course low-dose depot T i.m. is an effective, practical, safe, well tolerated, and inexpensive regimen. Some unresolved problems in management include optimal timing and dose of sex steroid treatment, the role of GH in CDGP, and the management of CDGP in girls.

Original languageEnglish
Pages (from-to)953-957
Number of pages5
JournalJournal of Pediatric Endocrinology and Metabolism
Issue numberSUPPL. 2
Publication statusPublished - 2001


  • Consensus guidelines
  • Constitutional delay of growth and puberty
  • Gonadotrophin
  • Growth
  • Puberty
  • Sex steroid treatment
  • Testosterone

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Management of puberty in constitutional delay of growth and puberty'. Together they form a unique fingerprint.

Cite this